Single-chain TNF receptor 2 agonist fusion proteins
AssigneeRelinia, Inc.
InventorsDavid C Foster, Lutz B Giebel, Leonard G Presta
Life of this patent
Estimating the term…
Abstract
This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-α receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
Claims20
A fusion protein comprising SEQ ID NO:
- 31, SEQ ID NO:32, SEQ ID NO:34 or SEQ ID NO:35.
A fusion protein comprising a sequence selected from the group consisting of SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119 and SEQ ID NO:120.
Dependencies are inferred from the claim text.